Skip to content

Schrodinger SDGR Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$0+100%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$160K
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$117.98M-3,595%
Revvity logo
RevvityRVTY
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.15B-41.8%
Enterprise value$984.71M-44.4%
P/S4.5×-4.0×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's gain/loss on asset sales?
Schrodinger (SDGR) reported gain/loss on asset sales of -$11K in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.